The Manufacturers Life Insurance Company Increases Position in Edwards Lifesciences Corporation $EW

The Manufacturers Life Insurance Company grew its position in Edwards Lifesciences Corporation (NYSE:EW) by 4.1% during the first quarter, Holdings Channel.com reports. The firm owned 1,401,187 shares of the medical research company’s stock after acquiring an additional 54,579 shares during the period. The Manufacturers Life Insurance Company’s holdings in Edwards Lifesciences were worth $112,206,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of EW. Hanson & Doremus Investment Management purchased a new stake in Edwards Lifesciences during the 1st quarter worth about $25,000. JPL Wealth Management LLC purchased a new stake in Edwards Lifesciences during the third quarter worth approximately $25,000. MV Capital Management Inc. acquired a new position in Edwards Lifesciences in the fourth quarter valued at approximately $26,000. RMG Wealth Management LLC acquired a new position in Edwards Lifesciences in the first quarter valued at approximately $26,000. Finally, Kemnay Advisory Services Inc. purchased a new position in Edwards Lifesciences in the fourth quarter valued at approximately $27,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $83.69 on Wednesday. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29. The stock has a 50 day moving average of $87.77 and a two-hundred day moving average of $83.85. The stock has a market cap of $48.19 billion, a P/E ratio of 48.10, a P/E/G ratio of 2.09 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. The business had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a return on equity of 15.85% and a net margin of 15.43%.The company’s revenue was up 13.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, research analysts forecast that Edwards Lifesciences Corporation will post 2.99 earnings per share for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the transaction, the senior vice president directly owned 15,334 shares in the company, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the company’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the sale, the vice president directly owned 98,611 shares of the company’s stock, valued at $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 45,577 shares of company stock worth $3,855,527 in the last 90 days. Company insiders own 0.31% of the company’s stock.

Analysts Set New Price Targets

EW has been the topic of a number of research analyst reports. Piper Sandler reissued an “overweight” rating and set a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a report on Friday. Evercore reaffirmed an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a research report on Monday, July 6th. Barclays reiterated an “overweight” rating and set a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Truist Financial boosted their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Finally, BTIG Research upped their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Seventeen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus target price of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.